Cargando…
Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors
Gastrointestinal stromal tumors represent the most common mesenchymal tumor of the digestive tract, driven by gain‐of‐function mutations in KIT. Despite its proven benefits, half of the patients treated with imatinib show disease progression within 2 years due to secondary resistance mutations in KI...
Autores principales: | Takahashi, Tsuyoshi, Elzawahry, Asmaa, Mimaki, Sachiyo, Furukawa, Eisaku, Nakatsuka, Rie, Nakamura, Hiromi, Nishigaki, Takahiko, Serada, Satoshi, Naka, Tetsuji, Hirota, Seiichi, Shibata, Tatsuhiro, Tsuchihara, Katsuya, Nishida, Toshirou, Kato, Mamoru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324566/ https://www.ncbi.nlm.nih.gov/pubmed/27997714 http://dx.doi.org/10.1002/gcc.22438 |
Ejemplares similares
-
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
por: Saito, Yurina, et al.
Publicado: (2019) -
A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing
por: Kato, Mamoru, et al.
Publicado: (2018) -
Impact of the KIT/PDGFRA genotype on prognosis in imatinib‐naïve Japanese patients with gastrointestinal stromal tumor
por: Cho, Haruhiko, et al.
Publicado: (2021) -
Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines
por: Nasuno, Tomomitsu, et al.
Publicado: (2014) -
Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)